Lung cancer has the highest mortality rate of all cancers worldwide. A total of 70%–75% of
all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with …

Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is
very poor. Currently, therapeutic methods for this patient population include whole-brain …

Brain metastasis (BM) has been universally recognized as a poor prognostic factor in non-
small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase …

Objective The objective of this study was to evaluate the efficacy and safety of icotinib in
patients with brain metastases (BMs) from lung adenocarcinoma. Patients and methods …

Purpose Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of …

Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer
patients. How to optimize the use of existing targeted drugs is an important way to address …

Central nervous system (CNS) metastases are a frequent and severe complication
associated with epidermal growth factor receptor (EGFR)-mutated non-small cell lung …

Background Non-small cell lung cancer (NSCLC) with brain metastases (M) had a poor
prognosis. Whole brain irradiation (WBI) is a standard of care for this critical medical …

Background Non-small-cell lung cancer (NSCLC) had poor prognosis in patients with brain
metastasis. The trial evaluated the safety and efficacy of epitinib (HMPL-813), an epidermal …

Background To evaluate the antitumor activity and toxicity of icotinib as initial treatment in
lung adenocarcinoma patients with brain metastases. Methods Twenty‐one patients with …